Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Psilocybin-assisted CBT for Depression
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 30
- Registration Number
- NCT05227612
- Locations
- ๐บ๐ธ
UCLA Semel Institute, Los Angeles, California, United States
Exploratory Study of Low Dose Psilocybin
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 60
- Registration Number
- NCT05227742
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
Psilocybin-assisted Therapy for Phantom Limb Pain
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 20
- Registration Number
- NCT05224336
- Locations
- ๐บ๐ธ
University of California, San Diego, San Diego, California, United States
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 24
- Registration Number
- NCT05220046
- Locations
- ๐บ๐ธ
University of Nebraska Medical Center, Omaha, Nebraska, United States
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
- Conditions
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sheppard Pratt Health System
- Target Recruit Count
- 20
- Registration Number
- NCT05220410
- Locations
- ๐บ๐ธ
Sheppard Pratt Health System, Baltimore, Maryland, United States
Naturalistic Study of Microdosing With Psilocybin
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2021-12-16
- Target Recruit Count
- 34
- Registration Number
- NCT05160220
- Locations
- ๐ฆ๐ท
Instituto de Fisica de Buenos Aires (IFIBA), Buenos Aires, Argentina
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Kevin Boehnke
- Target Recruit Count
- 7
- Registration Number
- NCT05128162
- Locations
- ๐บ๐ธ
Chronic Pain and Fatigue Research Center, Ann Arbor, Michigan, United States
Psilocybin-facilitated Treatment for Chronic Pain
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT05068791
- Locations
- ๐บ๐ธ
UAB Beacon Tower, Birmingham, Alabama, United States
Psilocybin for Treatment-Resistant Depression
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brain and Cognition Discovery Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT05029466
- Locations
- ๐จ๐ฆ
Canadian Rapid Treatment Centre of Excellence (CRTCE), Mississauga, Ontario, Canada
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Portland VA Research Foundation, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT04982796
- Locations
- ๐บ๐ธ
Portland VA Health Care System, Vancouver, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.